Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Cardiovascular disease is the leading cause of death in women. Decades of grassroots
campaigns have helped to raise awareness about the impact of cardiovascular disease in …

Abstract Background Emerging evidence from China suggests that coronavirus disease
2019 (COVID-19) is deadlier for infected men than women with a 2.8% fatality rate being …

Aims No therapy has shown to reduce the risk of hospitalization for heart failure across the
entire range of ejection fractions seen in clinical practice. We assessed the influence of …

The prevalence of type 2 diabetes mellitus is increasing in both sexes, but men are usually
diagnosed at a younger age and lower body fat mass than women. Worldwide, an estimated …

Background: Patients with heart failure with preserved ejection fraction have significant
impairment in health-related quality of life. In the EMPEROR-Preserved trial (Empagliflozin …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

In accordance with the comorbidity-inflammation paradigm, comorbidities and especially
metabolic comorbidities are presumed to drive development and severity of heart failure with …

It is estimated that half of all patients with heart failure (HF) have HF with preserved ejection
fraction (HFpEF). Yet this form of HF remains a diagnostic and therapeutic challenge …